4.17
Precedente Chiudi:
$4.00
Aprire:
$3.94
Volume 24 ore:
755.52K
Relative Volume:
0.84
Capitalizzazione di mercato:
$486.20M
Reddito:
$58.49M
Utile/perdita netta:
$-105.04M
Rapporto P/E:
-3.2084
EPS:
-1.2997
Flusso di cassa netto:
$-13.78M
1 W Prestazione:
-7.95%
1M Prestazione:
-4.79%
6M Prestazione:
-60.36%
1 anno Prestazione:
-61.14%
Immatics N V Stock (IMTX) Company Profile
Confronta IMTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
IMTX
Immatics N V
|
4.17 | 486.20M | 58.49M | -105.04M | -13.78M | -1.2997 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-07 | Iniziato | Piper Sandler | Overweight |
2023-11-02 | Iniziato | Cantor Fitzgerald | Overweight |
2023-03-31 | Iniziato | Mizuho | Buy |
2023-03-24 | Iniziato | Bryan Garnier | Buy |
2020-11-20 | Iniziato | BofA Securities | Buy |
2020-09-22 | Iniziato | Goldman | Buy |
2020-07-27 | Iniziato | SVB Leerink | Outperform |
2020-07-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Immatics N V Borsa (IMTX) Ultime notizie
Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Financial Contrast: Novonesis A/S (OTC:NVZMY) and Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Posts Earnings Results - MarketBeat
Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World
Immatics Reports Strong 2024 Financial Results and Progress - TipRanks
Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView
Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks
Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan
Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World
IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
(IMTX) Trading Report - Stock Traders Daily
Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World
Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex
Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World
(IMTX) Trading Signals - Stock Traders Daily
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat
abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat
Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance
Immatics N.V (IMTX): An Important Analyst Insights - Stocks Register
Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News
Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat
Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat
Immatics N.V (IMTX) Volatility Hits 4.72% – Here Is What You Should Do - Stocks Register
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
Brokers Offer Predictions for Immatics FY2025 Earnings - ETF Daily News
Cantor Fitzgerald Predicts Immatics FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Immatics FY2025 Earnings - MarketBeat
Is Immatics N.V. (IMTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in December - MarketBeat
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Immatics (NASDAQ:IMTX) Shares Down 3.9%What's Next? - MarketBeat
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround - Yahoo Finance
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price - Simply Wall St
Immatics N.V.: Considering More Engineered T Cells For Cancer (NASDAQ:IMTX) - Seeking Alpha
Immatics N V Azioni (IMTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):